<?xml version="1.0" encoding="UTF-8"?>
<p>Each individual will be invited to participate in a 28-day follow-up at day 0, day 2, day 4, day 7, day 14, day 21, day 28 after initiation of a specific antiviral regimen. Blood, nasopharyngeal swab, sputum, stool, and urine samples will be collected for laboratory examinations, which includes hematological analysis, urinalysis, hepatic and renal function test, test for serum amylase levels and myocardial enzyme levels, arterial blood gas analysis, thyroid function test, 2019-nCoV RNA qualification test, lymphocyte subsets test, coagulation test, and chest imaging examination. All data will be recorded in case report forms and in Microsoft Excel (Microsoft Corporation, Redmond, WA).</p>
